Effect of tumor-infiltrating lymphocytes depending on the presence of postmastectomy radiotherapy on the prognosis in pT1-2N1M0 breast cancer

被引:0
|
作者
Zhang, Lina [1 ]
Tang, Tiantian [1 ]
Liu, Lei [1 ]
Li, Chunxiao [1 ]
Li, Yuntao [1 ]
Geng, Cuizhi [1 ]
机构
[1] Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
tumor-infiltrating lymphocytes; breast cancer; postmastectomy radiotherapy; prognosis; local recurrence; CELL-DEATH; RADIATION; IMMUNOTHERAPY; CHEMOTHERAPY; TRASTUZUMAB; ESTROGEN; SURVIVAL; RECEPTOR;
D O I
10.3389/fonc.2023.1175965
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundCurrently, it remains unclear regarding the association between tumor-infiltrating lymphocytes (TILs) and the efficacy of postoperative radiotherapy in primary tumors. Here we attempted to investigate the effect of TILs depending on the presence of postmastectomy radiotherapy (PMRT) on the prognosis in pT1-2N1M0 breast cancer. MethodsThe clinical data of pT1-2N1M0 breast cancer patients undergoing mastectomy and axillary lymph node dissection were retrospectively analyzed. The effect of TILs on the prognosis was assessed based on the infiltration degree (low: TILs & LE;10%, high: TILs >10%), and then the prognosis of patients with low and high infiltration of TILs was analyzed based on presence or absence of PMRT. ResultsTotally 213 patients were eligible for the study, including 162 cases of low infiltration and 51 of high infiltration. High-infiltration patients tended to be ER/PR-negative, HER2-positive, and have high histological grade. The infiltration in triple-negative and HER2-positive subtypes was higher compared with Luminal A subtype. Regarding local-regional recurrence-free survival, recurrence-free survival, and overall survival (OS) rates, the differences were all inapparent whether in high- and low-infiltration patients or in high-infiltration patients with/without PMRT. Compared with those without PMRT, low-infiltration patients with PMRT showed a significantly increased OS rate (92.8% vs. 80.0%, p=0.023). Multivariate analysis further confirmed PMRT as an independent predicator of OS in low-infiltration patients (HR: 0.228, 95%CI: 0.081-0.644, p=0.005). ConclusionHigh infiltration of TILs in pT1-2N1M0 breast cancer may be associated with clinicopathological factors. Low-infiltration patients, but not high-infiltration patients, may derive survival benefits from PMRT.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Prognostic impact of lymph node ratio in patients with pT1-2N1M0 non-small cell lung cancer
    Shin, Sumin
    Kang, Danbee
    Cho, Jong Ho
    Choi, Yong Soo
    Kim, Jhingook
    Zo, Jae Ill
    Shim, Young Mog
    Kim, Hong Kwan
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5552 - +
  • [42] The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
    Li, Yanchun
    Opyrchal, Mateusz
    Yao, Song
    Peng, Xuan
    Yan, Li
    Jabbour, Hossam
    Khoury, Thaer
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 293 - 302
  • [43] Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
    Toru Hanamura
    Shigehisa Kitano
    Hiroshi Kagamu
    Makiko Yamashita
    Mayako Terao
    Banri Tsuda
    Takuho Okamura
    Nobue Kumaki
    Katsuto Hozumi
    Naoki Harada
    Takayuki Iwamoto
    Chikako Honda
    Sasagu Kurozumi
    Naoki Niikura
    [J]. Scientific Reports, 12
  • [44] Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
    Hanamura, Toru
    Kitano, Shigehisa
    Kagamu, Hiroshi
    Yamashita, Makiko
    Terao, Mayako
    Tsuda, Banri
    Okamura, Takuho
    Kumaki, Nobue
    Hozumi, Katsuto
    Harada, Naoki
    Iwamoto, Takayuki
    Honda, Chikako
    Kurozumi, Sasagu
    Niikura, Naoki
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
    Yanchun Li
    Mateusz Opyrchal
    Song Yao
    Xuan Peng
    Li Yan
    Hossam Jabbour
    Thaer Khoury
    [J]. Breast Cancer Research and Treatment, 2018, 170 : 293 - 302
  • [46] PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
    Wimberly, Hallie
    Brown, Jason R.
    Schalper, Kurt
    Haack, Herbert
    Silver, Matthew R.
    Nixon, Christian
    Bossuyt, Veerle
    Pusztai, Lajos
    Lannin, Donald R.
    Rimm, David L.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) : 326 - 332
  • [47] Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?
    Raghavan, Rajeev Kavalakara
    Ibrahim, Shabna
    Krishna, Jagathnath K. M.
    Mathew, Beela Sarah
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (05) : 1031 - 1034
  • [48] Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
    Vasiliki Pelekanou
    Daniel E. Carvajal-Hausdorf
    Mehmet Altan
    Brad Wasserman
    Cristobal Carvajal-Hausdorf
    Hallie Wimberly
    Jason Brown
    Donald Lannin
    Lajos Pusztai
    David L. Rimm
    [J]. Breast Cancer Research, 19
  • [49] The prognostic differences and the effect of postmastectomy radiotherapy between post-chemotherapy ypT1-2ypN1 and de novo pT1-2N1 breast cancer
    Yang, Tian
    Zhong, Xiaorong
    Wang, Jun
    Xiang, Zhongzheng
    Zeng, Yuanyuan
    Yu, Siting
    Dai, Zelei
    Xu, Ningyue
    Luo, Ting
    Liu, Lei
    [J]. CANCER MEDICINE, 2023, 12 (07): : 8112 - 8121
  • [50] Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial
    Kovacs, Aniko
    Tullberg, Axel Stenmark
    Ronnerman, Elisabeth Werner
    Holmberg, Erik
    Hartman, Linda
    Sjostrom, Martin
    Lundstedt, Dan
    Malmstrom, Per
    Ferno, Marten
    Karlsson, Per
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1179 - +